Refine
Has Fulltext
- yes (3)
Is part of the Bibliography
- yes (3)
Document Type
- Journal article (3)
Language
- English (3)
Keywords
- Active disease (1)
- Acute myeloid leukemia (1)
- Acute myeloid leukemia (AML) (1)
- Allogeneic stem cell transplantation (1)
- Allogeneic transplantation (1)
- Blood (1)
- Conditioning regimen (1)
- Elderly (1)
- European group (1)
- Fludarabine (1)
- Fludarabine-treosulfan (FT) (1)
- Gruppo-italiano (1)
- Haploidentical (1)
- LATE DEATHS (1)
- Late mortality (1)
- MUD (1)
- Midollo-Osseo (1)
- Prognostic scoring system (1)
- Ruxolitinib (1)
- Sibling donor (MSD) (1)
- Societe Francaise (1)
- Survival (1)
- Thiotepa-busulfan-fludarabine (TBF) (1)
- Unrelated donor (UD) (1)
- amsacrine (1)
- cyclophosphamide (FLAMSA) (1)
- intermediate dose Ara-C (1)
- total body irradiation/busulfan (1)
Institute
Background: Acute myeloid leukemia (AML) is both more common and with more biologically aggressive phenotype in the elderly. Allogenic stem cell transplantation (allo-SCT) is the best treatment option in fit patients. Either HLA-matched unrelated donor (MUD) or haploidentical (Haplo) donor are possible alternative for patients in need. Methods: We retrospectively compared non-T-cell-depleted Haplo (n = 250) to 10/10 MUD (n = 2589) in AML patients >= 60 years. Results: Median follow-up was 23 months. Disease status at transplant differs significantly between the two groups (p < 10(-4)). Reduced intensity conditioning (RIC) was administrated to 73 and 77% of Haplo and MUD, respectively (p = 0.23). Stem cell source was the bone marrow (BM) in 52% of the Haplo and 6% of MUD (p < 10(-4)). Anti-thymocyte globulin (ATG) was most frequently used in MUD (p < 10(-4)) while post-Tx cyclophosphamide (PT-Cy) was given in 62% of Haplo. Engraftment was achieved in 90% of the Haplo vs 97% of MUD (p < 10(-4)). In multivariate analysis, no significant difference was found between Haplo and MUD for acute (a) graft versus host disease (GVHD) grade II-IV, relapse incidence (RI), non-relapse mortality (NRM), leukemia free survival (LFS), graft-versus-host-free-relapse free survival (GRFS), and overall survival (OS). Extensive chronic (c) GVHD was significantly higher for MUD as compared to Haplo (HR 2, p = 0.01, 95% CI 1.17-3.47). A propensity score analysis confirmed the higher risk of extensive cGVHD for MUD without differences for other outcomes. Conclusions: Allo-SCT from both Haplo and MUD are valid option for AML patients >= 60 years of age with similar results. Transplantation from MUD was associated with higher extensive cGVHD. Our findings suggest that Haplo is a suitable and attractive graft source for patients >= 60 with AML in need of allo-SCT.